Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial

Authors: Jordi Remon, MD, Benjamin Besse, MD, PhD, Alexandra Leary, MD, PhD, Ivan Bièche, MD, Bastien Job, MD, Ludovic Lacroix, PhD, Aurélie Auguste, PhD, Marjorie Mauduit, PhD, Clarisse Audigier-Valette, MD, Judith Raimbourg, MD, Anne Madroszyk, MD, Stefan Michels, MD, Mohammed Amine Bayar, MD, Marta Jimenez, PhD, Jean-Charles Soria, MD, PhD, Etienne Rouleau, PhD, PharmD, MPH, Fabrice Barlesi, MD, PhD

Source: JTO Clinical and Research Reports, Vol 1, Iss 3, Pp 100068- (2020)

Subject Terms: BRCA mutation, Advanced non–small cell lung cancer, PARP inhibitors, Next-generation sequencing, SAFIR trial, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2666364320300916; https://doaj.org/toc/2666-3643

Access URL: https://doaj.org/article/cb706811cafb4c91896d59398b20d6b7